Upon application of atezolizumab, an mAb medication against PD-L1, PD-L1+ NK cells express significantly increased levels of granzyme B, IFN-γ, and CD107a, which results in a significant increase in antitumor activity and ultimately a significant decrease in tumor burden in mice (8). The gene discussed is GZMB; the disease is neoplasm.